Mylan launches UK insulin glargine rival

Mylan has launched in the UK the Semglee (insulin glargine) biosimilar that it developed with Biocon. Available in 100 units/ml pre-filled pens, the once-a-day long-acting basal insulin is indicated to treat diabetes mellitus in adults and children above two years of age.